Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ocugen, Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing modifier gene therapies for retinal diseases. Form 8-K disclosures cover clinical and Regulation FD updates for programs including OCU410, capital-structure events such as warrant exercises and 6.75% convertible senior notes due 2034, and material agreements tied to the note indenture and loan repayment.
Proxy materials describe annual meeting proposals, shareholder voting matters, and governance practices. Other filings identify the company's common stock on The Nasdaq Capital Market, preliminary financial information, authorized-share validation matters, and furnished investor presentations containing forward-looking clinical-development statements.
Ocugen, Inc. has signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa. Under the contemplated license, Ocugen expects upfront and near-term development milestone payments totaling up to $4 million, potential sales milestone payments up to $255 million, and a 22% royalty on net sales of OCU400 in the territory. Ocugen would also supply commercial product under a related supply agreement. A definitive agreement is expected within 90 days. OCU400 is being evaluated in the Phase 3 liMeliGhT program, with topline data anticipated in 1Q 2027 followed by a planned BLA submission.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene bought 21,000 shares of Common Stock in an open-market purchase at $1.23 per share. Following this transaction, she directly holds 521,000 shares and has indirect ownership of 350 shares held by her spouse.
Ocugen, Inc. director Uday Kompella received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided he continues serving through the vesting date. Following this grant, Kompella holds 170,100 options directly.
Ocugen, Inc. director Chandrasekhar Satishchandran received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.
The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, subject to his continued service through the vesting date. After this grant, his reported derivative holdings in this award total 170,100 options.
Ocugen, Inc. director Kirsten Castillo received a grant of stock options as equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036.
The options vest upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided she continues to serve through the vesting date. Following this grant, she holds 170,100 derivative securities related to common stock.
Ocugen, Inc. director Junge Zhang received a grant of stock options on June 11, 2026 as part of equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036. The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, contingent on continued service through the vesting date. Following this grant, the filing shows Zhang holding 170,100 derivative securities directly, with no open‑market purchases or sales reported.
Ocugen, Inc. director Blaise Coleman received a new stock option grant covering 170,100 shares of common stock. The option has an exercise price of $1.22 per share and expires on June 11, 2036. This is a compensation-related award, not an open-market purchase.
According to the terms, the option vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, provided Coleman continues to serve through the applicable vesting date. Following this grant, he holds 170,100 stock options directly.
Ocugen, Inc. reported results from its 2026 Annual Meeting of Stockholders and confirmed a key leadership change. Stockholders elected Kirsten Castillo and Satish Chandran as Class III directors, with 56,242,944 and 62,604,983 votes in favor, respectively. PricewaterhouseCoopers LLP was ratified as independent auditor for the 2026 fiscal year with 136,784,245 votes for and 1,002,550 against.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers, with 49,968,948 votes for and 13,245,090 against. They also indicated a preference to hold future advisory votes on executive pay every year, supported by 57,545,540 votes for a one-year frequency. The Board decided to follow this annual frequency. In addition, Ocugen appointed Mohamed Genead as Chief Medical Officer effective June 11, 2026, transitioning him from his prior Acting/Interim role.
Ocugen, Inc. reports a leadership change in its finance function. Effective May 29, 2026, Ramesh Ramachandran resigned as Chief Accounting Officer, a role that also carried responsibility as principal accounting officer.
Following his resignation, on June 3, 2026, Chief Financial Officer Rita Johnson-Greene was appointed as principal accounting officer. Her employment terms and background were previously described in a Form 8-K filed on February 9, 2026. The company states there are no special arrangements behind her appointment, no family relationships with directors or executives, and no related-party transactions requiring disclosure.
Ocugen, Inc. reported a leadership change in its medical organization. Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer. On the same date, Ocugen appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer, ensuring continuity of senior medical leadership while the company evaluates longer-term plans for the role.